Literature DB >> 18285752

Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.

Marc A Dall'Era1, Badrinath R Konety.   

Abstract

The natural history of prostate cancer is often of long duration, and the disease is incompletely understood. Whether all men with prostate cancer require immediate treatment or whether men with tumors of low malignant potential are being overtreated with potentially harmful therapies is a subject of much debate. Results from a randomized trial that compared watchful waiting and active therapy showed all-cause and disease-specific survival advantages with radical therapy, but the study group was mixed in terms of disease risk; the optimum treatment strategy for men with low risk features remains unclear. Multiple centers are gaining experience with active surveillance and delayed intervention with curative intent for men with prostate tumors of potentially low clinical risk. This Review describes the background studies behind the rationale for active surveillance, thoughts on selection criteria for candidates and some early reported outcomes for active surveillance cohorts. The psychosocial impact of active surveillance on patients is discussed as well as contemporary methods for disease monitoring.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285752     DOI: 10.1038/ncpuro1058

Source DB:  PubMed          Journal:  Nat Clin Pract Urol        ISSN: 1743-4270


  8 in total

1.  Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments.

Authors:  Deborah J del Junco; Erin E Fox; Sharon Cooper; Marc Goldhagen; Erik Koda; David Rogers; Edith Canby-Hagino; Jeri Kim; Curtis Pettaway; Douglas D Boyd
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

2.  Utilization and predictors of expectant management among elderly men with low-and intermediate-risk localized prostate cancer in U.S. urological practice.

Authors:  Huei-Ting Tsai; George Philips; Kathryn L Taylor; Keith Kowalczyk; Kuo Huai-Ching; Arnold L Potosky
Journal:  Urol Pract       Date:  2017-03

3.  Regional, provider, and economic factors associated with the choice of active surveillance in the treatment of men with localized prostate cancer.

Authors:  Ann S Hamilton; Xiao-Cheng Wu; Joseph Lipscomb; Steven T Fleming; Mary Lo; Dian Wang; Michael Goodman; Alex Ho; Jean B Owen; Chandrika Rao; Robert R German
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

4.  Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring.

Authors:  Jenny L Donovan
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

5.  Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.

Authors:  Jeri Kim; James Ebertowski; Matthew Janiga; Jorge Arzola; Gayle Gillespie; Michael Fountain; Douglas Soderdahl; Edith Canby-Hagino; Sally Elsamanoudi; Jennifer Gurski; John W Davis; Patricia A Parker; Douglas D Boyd
Journal:  BJU Int       Date:  2013-01-25       Impact factor: 5.588

6.  Algorithms, nomograms and the detection of indolent prostate cancer.

Authors:  Monique J Roobol
Journal:  World J Urol       Date:  2008-06-07       Impact factor: 4.226

7.  Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.

Authors:  Jeong S Han; Adam D Toll; Ali Amin; H Ballentine Carter; Patricia Landis; Stephen Lee; Jonathan I Epstein
Journal:  Urology       Date:  2012-08-22       Impact factor: 2.649

8.  Treatment and Mortality in Men with Localized Prostate Cancer: A Population-Based Study in California.

Authors:  Weiva Sieh; Daphne Y Lichtensztajn; David O Nelson; Myles Cockburn; Dee W West; James D Brooks; Ellen T Chang
Journal:  Open Prost Cancer J       Date:  2013
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.